SCHEDULE: 5AM Ventures trims Entrada stake in 13D update

5AM Ventures and affiliates disclosed selling 200,000 Entrada shares and updated beneficial ownership stakes ranging from 2.9% to 10.8%.

Summary

• Amendment No. 1 to Schedule 13D by 5AM Ventures affiliates regarding Entrada Therapeutics, Inc. common stock (CUSIP 29384C108).
• Event date: November 14, 2025; 5AM Ventures V, L.P. sold 200,000 shares in open-market transactions at prices ranging from $8.80 to $9.023 (weighted average $8.80).
• Beneficial ownership (based on 38,219,232 shares outstanding as of October 31, 2025): 5AM Ventures V, L.P. holds 2,963,066 shares (7.8%); 5AM Opportunities I, L.P. holds 1,093,313 shares (2.9%).
• Individual reporting persons: Andrew J. Schwab beneficially owns 4,056,379 shares (10.6%); Kush Parmar beneficially owns 4,123,849 shares (10.8%), including 67,470 vested stock options; Scott M. Rocklage beneficially owns 2,963,066 shares (7.8%).
• General partners share voting and dispositive power over the securities held by the applicable funds as described (5AM Partners V, LLC for 5AM Ventures V; 5AM Opportunities I (GP), LLC for 5AM Opportunities I).
• No other transactions by the reporting persons in the past 60 days.
• Ownership percentages are calculated using the issuer’s reported 38,219,232 shares outstanding as of October 31, 2025 (Form 10-Q filed November 6, 2025).
• Signatures executed on November 18, 2025 by the reporting persons.

Sentiment

Score: 5

Explanation: Neutral to slightly negative: a modest insider sale occurred, but reporting persons retain significant ownership and there are no operational or governance changes disclosed.

Positives

• Reporting persons remain significant holders (e.g., Kush Parmar at 10.8% and Andrew J. Schwab at 10.6%), signaling continued alignment with shareholders.
• Clear disclosure of a 200,000-share open-market sale with stated price range ($8.80–$9.023) and weighted average ($8.80).
• Ownership structure and voting/dispositive power are explicitly outlined across funds and general partners.

Negatives

• Insider selling: 5AM Ventures V, L.P. sold 200,000 shares on November 14, 2025 at a weighted average price of $8.80, indicating a reduction in stake.
• Aggregate control by reporting persons remains high, which can be a governance overhang for some investors despite no change in control disclosed.

Future Outlook

No guidance or forward-looking statements are provided; the amendment solely updates beneficial ownership and recent share sale details.

Management Comments

• On November 14, 2025, 5AM Ventures V, L.P. sold an aggregate of 200,000 shares in open-market transactions at prices ranging from $8.80 to $9.023 (weighted average $8.80).
• No other transactions with respect to the issuer’s securities were effected by the reporting persons during the past sixty days.
• No other person is known to have the right to receive or direct the receipt of dividends or sale proceeds from the securities beneficially owned by the reporting persons.
• Ownership percentages are based on 38,219,232 shares outstanding as of October 31, 2025, as reported in the issuer’s Form 10-Q filed November 6, 2025.

Industry Context

Venture investors in biotechnology often rebalance positions post-IPO or following program milestones; partial open-market sales while maintaining significant ownership stakes are common and typically reflect portfolio management rather than an operational signal from the issuer.

Comparison to Industry Standards

• The reported stakes (approximately 3% to 11%) align with typical venture or specialist biotech fund holdings post-IPO, similar in magnitude to positions often disclosed by firms like RA Capital or RTW in comparable small- to mid-cap biotech issuers.
• A 200,000-share open-market sale without crossing a major regulatory threshold (e.g., 10% for certain insiders, 5% for Schedule 13D/13G) is consistent with routine liquidity management seen across the sector.
• Continued holdings above 10% by certain managers remain within normal practice for lead venture backers in early-stage biotech.

Stakeholder Impact

• Increases public float by 200,000 shares, potentially improving trading liquidity.
• Significant continuing ownership by reporting persons (up to 10.8%) indicates ongoing influence in shareholder matters.
• No operational changes or governance actions disclosed; impact is limited to share ownership dynamics.

Key Dates

Recommendation

The amendment reflects a partial sell-down by a major holder but maintains substantial ownership positions. Without issuer operational updates or financial results, the filing alone does not warrant a change in investment stance.

Keywords

Schedule 13D, Entrada Therapeutics, 5AM Ventures, beneficial ownership, insider selling, CUSIP 29384C108, open market transaction, venture capital, biotech, ownership percentage